While investors await the initial Phase III data readouts for new drugs in non-alcoholic steatohepatitis (NASH) in 2019, a pair of companies long involved in the race to bring the first NASH therapy to market experienced divergent fates this past week. Conatus Pharmaceuticals Inc. got its second mid-stage setback with NASH candidate emricasan, failing to meet a Phase IIb primary endpoint in portal hypertension, while Genfit SA reported Phase II success with elafibranor in primary biliary cholangitis (PBC).
Emricasan, a first-in-class pan-caspase inhibitor for which Novartis AG has held option rights since 2016, is currently being studied...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
